


# Diagnostic algorithm<sup>1</sup>

Differential diagnosis for primary TMAs (including ADAMTS13)<sup>1</sup>




\* Shiga-toxin/EHEC test is warranted in history/presence of GI symptoms.

ADAMTS13, A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 13; eGFR, estimated Glomerular Filtration Rate; EHEC, Enterohemorrhagic *E. coli*; LDH, Lactate Dehydrogenase; STEC-HUS, Shiga-Toxin-Producing *E. coli* Hemolytic Uremic Syndrome; TMA, Thrombotic Microangiopathy; TTP, Thrombotic Thrombocytopenic Purpura.

1. Laurence J, et al. Clin Adv Hematol Oncol. 2016 14 Suppl 11(11):2-15.

# Diagnostic algorithm<sup>1</sup>

Patient approach to a TMA associated with a complement-amplifying condition<sup>1</sup>



\* Shiga-toxin/EHEC test is warranted in history/presence of GI symptoms.

ADAMTS13, A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 13; eGFR, estimated Glomerular Filtration Rate; EHEC, Enterohemorrhagic E. coli; LDH, Lactate Dehydrogenase; TMA, Thrombotic Microangiopathy; CAC, Complement-amplifying condition; MHT, Malignant Hypertension; SLE, Systemic Lupus Erythematosus.

1. Laurence J, et al. Clin Adv Hematol Oncol. 2016 14 Suppl 11(11):2-15.